Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis: A Cohort Study
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Background: Low-dose glucocorticoids are frequently used for the management of rheumatoid arthritis (RA) and other chronic conditions, but the safety of long-term use remains uncertain. Objective: To quantify the risk for hospitalized infection with long-term use of low-dose glucocorticoids in patients with RA receiving stable disease-modifying antirheumatic drug (DMARD) therapy. Design: Retrospective cohort study. Setting: Medicare claims data and Optum's deidentified Clinformatics Data Mart database from 2006 to 2015. Patients: Adults with RA receiving a stable DMARD regimen for more than 6 months. Measurements: Associations between glucocorticoid dose (none, ≤5 mg/d, >5 to 10 mg/d, and >10 mg/d) and hospitalized infection were evaluated using inverse probability–weighted analyses, with 1-year cumulative incidence predicted from weighted models. Results: 247 297 observations were identified among 172 041 patients in Medicare and 58 279 observations among 44 118 patients in Optum. After 6 months of stable DMARD use, 47.1% of Medicare patients and 39.5% of Optum patients were receiving glucocorticoids. The 1-year cumulative incidence of hospitalized infection in Medicare patients not receiving glucocorticoids was 8.6% versus 11.0% (95% CI, 10.6% to 11.5%) for glucocorticoid dose of 5 mg or less per day, 14.4% (CI, 13.8% to 15.1%) for greater than 5 to 10 mg/d, and 17.7% (CI, 16.5% to 19.1%) for greater than 10 mg/d (all P < 0.001 vs. no glucocorticoids). The 1-year cumulative incidence of hospitalized infection in Optum patients not receiving glucocorticoids was 4.0% versus 5.2% (CI, 4.7% to 5.8%) for glucocorticoid dose of 5 mg or less per day, 8.1% (CI, 7.0% to 9.3%) for greater than 5 to 10 mg/d, and 10.6% (CI, 8.5% to 13.2%) for greater than 10 mg/d (all P < 0.001 vs. no glucocorticoids). Limitation: Potential for residual confounding and misclassification of glucocorticoid dose. Conclusion: In patients with RA receiving stable DMARD therapy, glucocorticoids were associated with a dose-dependent increase in the risk for serious infection, with small but significant risks even at doses of 5 mg or less per day. Clinicians should balance the benefits of low-dose glucocorticoids with this potential risk. Primary Funding Source: National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Additional studies have corroborated these findings, linking even low dose glucocorticoid use (prednisone 2.5-7.5 mg/day) to increased risks of cardiovascular disease (9), severe infections (10), hypertension (11), diabetes (12), osteoporosis and fractures (13, 14), and increased overall mortality with concurrent type 2 diabetes mellitus (15).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Constructing Inverse Probability Weights for Marginal Structural Models
Cole, S. R., & Hernan, M. A. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn164 · Cited by 2,796 · cited 1×
“Propensity scores were used to create stabilized inverse probability treatment weights (26–28) truncated at the first and 99th percentiles (29).”
Method2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39480 · Cited by 2,777
Self-citationSmolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 2,057 · cited 5×
“They are widely accepted for short-term use as bridging therapy in patients starting or changing treatment with DMARDs (4, 5), with the goal of their eventual withdrawal.”
BackgroundInfluentialA tutorial on propensity score estimation for multiple treatments using generalized boosted models
McCaffrey, D. F., Griffin, B. A., Almirall, D., Slaughter, M. E., Ramchand, R., & Burgette, L. F. (2013) · Statistics in Medicine · doi:10.1002/sim.5753 · Cited by 1,450
A combined comorbidity score predicted mortality in elderly patients better than existing scores
Gagne, J. J., Glynn, R. J., Avorn, J., Levin, R., & Schneeweiss, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.10.004 · Cited by 995 · cited 2×
“Covariates measured during the baseline period included age, sex, race, geographic region, calendar year, comorbidities, an adaption of the Charlson Comorbidity Index (23), health care use (outpatient visits, rheumatologist outpatient visits, emergency department visits, and hospitalizations), previous hospitalized in…”
BackgroundSchneeweiss, S. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1200 · Cited by 727 · cited 1×
“To assess the effect of an unmeasured confounder (disease activity) on results, we did a residual bias assessment (30) using C-reactive protein (CRP) level in a subset of patients in Optum.”
MethodSingh, J. A., Cameron, C., Noorbaloochi, S., Cullis, T., Tucker, M., Christensen, R., Ghogomu, E. T., Coyle, D., Clifford, T., Tugwell, P., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61704-9 · Cited by 623
Wolfe, F., Caplan, L., & Michaud, K. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21568 · Cited by 480
Curtis, J. R., Patkar, N., Xie, A., Martin, C., Allison, J. J., Saag, M., Shatin, D., & Saag, K. G. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22504 · Cited by 398 · cited 1×
“The primary outcome definition was the presence of an ICD-9 diagnosis of infection (Supplement Table 1) in any position of the discharge diagnoses from an acute care hospitalization (positive predictive value >80%) (13, 22).”
BackgroundSelf-citationGrijalva, C. G., Chen, L., Delzell, E., Baddley, J. W., Beukelman, T., Winthrop, K. L., Griffin, M. R., Herrinton, L. J., Liu, L., Ouellet-Hellstrom, R., et al. (2011) · JAMA · doi:10.1001/jama.2011.1692 · Cited by 350
Self-citation
Cited by
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
Hellmich, B., Sanchez-Alamo, B., Schirmer, J. H., Berti, A., Blockmans, D., Cid, M. C., Holle, J. U., Hollinger, N., Karadag, O., Kronbichler, A., et al. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223764 · Cited by 768
Rheumatoid Arthritis — Common Origins, Divergent Mechanisms
Gravallese, E. M., & Firestein, G. S. (2023) · New England Journal of Medicine · doi:10.1056/nejmra2103726 · Cited by 752
Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Pofi, R., Caratti, G., Ray, D. W., & Tomlinson, J. W. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad016 · Cited by 209
“However, several retrospective studies have suggested that lower doses ( ≤ 5 mg PE/day) are also associated with a clinically meaningful increase in serious infection risk (388, 390, 394), especially when given for a prolonged duration ( > 3 months) (391).”
BackgroundBeuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae250 · Cited by 172
Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L. T., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae029 · Cited by 157
Excess Uric Acid Induces Gouty Nephropathy Through Crystal Formation: A Review of Recent Insights
Mei, Y., Dong, B., Geng, Z., & Xu, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.911968 · Cited by 144
England, B. R., Roul, P., Yang, Y., Kalil, A. C., Michaud, K. D., Thiele, G. M., Sauer, B. C., Baker, J. F., & Mikuls, T. R. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41800 · Cited by 133
“Similar risks have been identified in RA patients with b/tsDMARDs and prednisone for nonCOVID-19 severe infections (28, 29).”
BackgroundSelf-citationBergstra, S. A., Sepriano, A. R., Kerschbaumer, A., van der Heijde, D. M. F. M., Caporali, R. F., Edwards, C. J., Verschueren, P., de Souza, S., Pope, J. E., Takeuchi, T., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223358 · Cited by 131
Self-citationOcon, A. J., Reed, G., Pappas, D. A., Curtis, J. R., & Kremer, J. M. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220577 · Cited by 96
Self-citationManagement of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities
Stamp, L. K., Farquhar, H. J., Pisaniello, H. L., Vargas‐Santos, A. B., Fisher, M. C., Mount, D. B., Choi, H. K., Terkeltaub, R. A., Hill, C. L., & Gaffo, A. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00657-4 · Cited by 109
Waiting for JAK inhibitor safety data
Kragstrup, T. W., Glintborg, B., Svensson, A.-M., McMaster, C., Robinson, P. C., Deleuran, B. W., & Liew, D. F. L. (2022) · RMD Open · doi:10.1136/rmdopen-2022-002236 · Cited by 96
Aletaha, D., Kerschbaumer, A., Kastrati, K., Dejaco, C., Dougados, M., McInnes, I. B., Sattar, N. A., Stamm, T., Takeuchi, T., Trauner, M., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-222784 · Cited by 91
Self-citationRisk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
Riley, T. R., & George, M. (2021) · RMD Open · doi:10.1136/rmdopen-2020-001235 · Cited by 88
“14 Notably, this infection risk is similar in magnitude to infection risk with TNFi.”
Self-citationButtgereit, F., Aelion, J. A., Rojkovich, B., Zubrzycka‐Sienkiewicz, A., Chen, S., Yang, Y., Arikan, D., D’Cunha, R., Pang, Y., Küpper, H., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42415 · Cited by 65
Nasonov, E. L., Lila, A. M., Vi, M., Belov, B. S., Karateev, A. E., Дубинина, Т. В., Nikitinskaya, O. A., Baranov, A. A., Abdulganieva, D. I., Moiseev, S. V., et al. (2021) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2021-239-254 · Cited by 63
Johnson, T. M., Yang, Y., Roul, P., Sauer, B. C., Cannon, G. W., Kunkel, G. A., Michaud, K. D., Baker, J. F., Mikuls, T. R., & England, B. R. (2022) · Arthritis Care & Research · doi:10.1002/acr.25053 · Cited by 53
“These findings illustrate the need for provider vigilance toward infectious disease prevention, including counseling on recommended vaccinations, minimizing glucocorticoid use and dose (38), and carefully considering risks when initiating biologic and targeted synthetic DMARDs.”
Self-citationBacterial infections in patients hospitalized with COVID-19
Moreno‐Torres, V., de Mendoza, C., de la Fuente, S., Sánchez, E., Martínez‐Urbistondo, M., Herráiz, J., Gutiérrez, A., Gutiérrez, Á., Hernández, C., Callejas, A., et al. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02824-7 · Cited by 52
Xie, W., Huang, H., Li, G., Hao, Y., Gui, Y., Wang, Y., Deng, X., Zhao, J., Geng, Y., Ji, L., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220112 · Cited by 46
Nanomedicines Targeting Respiratory Injuries for Pulmonary Disease Management
Liu, D., Long, M., Gao, L., Chen, Y., Fang, L., Shi, Y., & Gu, N. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202112258 · Cited by 52
Lu, B., Li, C., Jing, L., Zhuang, F., Xiang, H., Chen, Y., & Huang, B. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.012 · Cited by 47
Wallace, B. I., Tsai, H., Lin, P., Aasbjerg, K., Wu, A. C., Tsai, Y., Torp-Pedersen, C. T., Waljee, A. K., & Yao, T. (2023) · Clinical and Translational Science · doi:10.1111/cts.13649 · Cited by 43
“6,9,27 As these risks persist in young, otherwise healthy individuals, the population-level harms of short-term OCS exposure remain a critical concern even when clinicians avoid prescribing to elderly or comorbid “high-risk” patients.”
BackgroundDoumen, M., Pazmiño, S., Bertrand, D., Westhovens, R., & Verschueren, P. (2022) · Joint Bone Spine · doi:10.1016/j.jbspin.2022.105491 · Cited by 42
Effect of DMARDs on the immunogenicity of vaccines
van Sleen, Y., van der Geest, K. S. M., Huckriede, A. L. W., van Baarle, D., & Brouwer, E. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-00992-8 · Cited by 45
Coburn, B. W., Baker, J. F., Hsu, J. Y., Wu, Q., Xie, F., Curtis, J. R., & George, M. (2024) · Arthritis & Rheumatology · doi:10.1002/art.42928 · Cited by 40
“Taken together with studies suggesting increased infection risk even with low-dose glucocorticoids, 6,8 these results support weighing the risks with potential bene fi ts when deciding to treat with glucocorticoids and attempting glucocorticoid tapering after a new DMARD is initiated.”
Self-citationHarigai, M., Kaneko, Y., Tanaka, E., Hirata, S., Kameda, H., Kaneko, K., Kishimoto, M., Kohno, M., Kojima, M., Kojima, T., et al. (2025) · Modern Rheumatology · doi:10.1093/mr/roaf006 · Cited by 40
Li, C., Zheng, X. C., Hu, M. L., Jia, M., Jin, R., & Nie, Y. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2094364 · Cited by 34
Abe, K., Ishikawa, Y., Kita, Y., Yajima, N., Inoue, E., Sada, K., Miyawaki, Y., Yoshimi, R., Shimojima, Y., Ohno, S., et al. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02869-9 · Cited by 34
Biosimilars: A Critical Review of Development, Regulatory Landscape, and Clinical Implications
Monga, A., Gagan, Jamwal, P., Sharma, S., & Kaur, A. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-025-03038-2 · Cited by 28
“For instance, hospitals and clinics can invest savings in advanced diagnostic tools or patient care programs [92].”
Wells, A. U., Lower, E. E., Baughman, R. P., Culver, D. A., Judson, M. A., Bonham, C. A., Gerke, A. K., Grutters, J. C., Knoet, C., Martone, F., et al. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(25)00338-8 · Cited by 33
Immune Effects of Macrophages in Rheumatoid Arthritis: A Bibliometric Analysis From 2000 to 2021
Xu, Y., Zhang, Z., He, J., & Chen, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.903771 · Cited by 29
A Phase 3 Trial of Brepocitinib in Dermatomyositis
Vleugels, R. A., Paik, J. J., Ventura, I. B., Mangold, A. R., Gandiga, P. C., Haemel, A. K., Chinoy, H., Hussain, Y. M., Sivakumar, K., Griger, Z., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2503531 · Cited by 27
On the road to eliminating long‐lived plasma cells—“are we there yet?”
Markmann, C., & Bhoj, V. G. (2021) · Immunological Reviews · doi:10.1111/imr.13015 · Cited by 29
Husni, M. E., Deodhar, A., Schwartzman, S., Chakravarty, S. D., Hsia, E. C., Leu, J. H., Zhou, Y., Lo, K. H., & Kavanaugh, A. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02753-6 · Cited by 27
“even with doses ≤ 5 mg/day (prednisone or equivalent) [29].”
Backgroundvan Ouwerkerk, L., Boers, M., Emery, P., de Jong, P. H. P., Landewé, R., Lems, W. F., Smolen, J. S., Verschueren, P., Huizinga, T. W. J., Allaart, C. F., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223443 · Cited by 26
Gregory, M. H., Spec, A., Stwalley, D. L., Gremida, A. K., Mejía-Chew, C., Nickel, K. B., Ciorba, M. A., Rood, R. P., Olsen, M. A. A., & Deepak, P. (2023) · Crohn s & Colitis 360 · doi:10.1093/crocol/otad010 · Cited by 28
Barbulescu, A., Sjölander, A., Delcoigne, B., Askling, J., & Frisell, T. (2023) · Rheumatology · doi:10.1093/rheumatology/kead083 · Cited by 26
Liang, F., Tsai, H., Kuo, P., & Tsai, P. (2021) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.16677 · Cited by 25
Ren, J., Duan, S., Wu, Y., Wen, M., Zhang, J., Liu, Y., & Zhu, G. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03488-1 · Cited by 23
“Previous studies have shown that long-term use of high-dose glucocorticoid is associated with infection and other adverse effects, but a recent retrospective cohort study also found that even lowdose glucocorticoid were associated with a statistically significant increased risk of clinical in-patient infection [25, 26…”
Zhang, Z., Wan, H., Han, J., Sun, X., Yu, R., Liu, B., Lu, C., Zhou, J., & Su, X. (2022) · Journal of Functional Foods · doi:10.1016/j.jff.2022.105076 · Cited by 23
Precision Medicine in Rheumatic Diseases: Unlocking the Potential of Antibody-Drug Conjugates
Huang, Z., Braunstein, Z., Chen, J., Wei, Y., Rao, X., Dong, L., & Zhong, J. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001084 · Cited by 24
“An observational study indicated that even when the prednisone dose is < 5 mg/day, prolonged usage could still lead to severe adverse effects (George et al., 2020; Pujades-Rodriguez et al., 2020; Roubille et al., 2021).”
van Ouwerkerk, L., Palmowski, A., Nevins, I. S., Buttgereit, F., Verschueren, P., Smolen, J. S., Landewé, R., Bijlsma, J. W. J., Kerschbaumer, A., Westhovens, R., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2022-222338 · Cited by 23
Diagnosing giant cell arteritis: a comprehensive practical guide for the practicing rheumatologist
Andel, P. M., Chrysidis, S., Geiger, J., Haaversen, A. C. B., Haugeberg, G., Myklebust, G., Nielsen, B. D., & Diamantopoulos, A. P. (2021) · Rheumatology · doi:10.1093/rheumatology/keab547 · Cited by 21
Glucocorticoid and opioid use in rheumatoid arthritis management
Moore, M. N., & Wallace, B. I. (2021) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000788 · Cited by 19
Understanding the immunopathophysiology of polymyalgia rheumatica: implications for treatment
Choy, E., Unizony, S. H., Wells, A. F., Dasgupta, B., Buttgereit, F., & Tanaka, Y. (2025) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2025.09.005 · Cited by 19
Lv, K., Lou, P., Liu, S., Wang, Y., Yang, J., Zhou, P., Zhou, X., Lu, Y., Wang, H., Cheng, J., et al. (2023) · Small · doi:10.1002/smll.202303425 · Cited by 18
Lee, J., Martindale, J., Makris, U. E., Singh, N., Yung, R. L., & Bynum, J. (2023) · ACR Open Rheumatology · doi:10.1002/acr2.11625 · Cited by 18
“17 Therefore, especially if able to reduce long-term GC use, older adults with LORA may achieve improved quality of life, better outcomes, and less disability with more aggressive treatment with DMARDs, provided they are appropriately screened and monitored for associated risks.”
BackgroundFibromyalgianess and glucocorticoid persistence among patients with rheumatoid arthritis
Wallace, B. I., Moore, M. N., Heisler, A. C., Muhammad, L. N., Song, J., Clauw, D. J., Bingham, C. O., Bolster, M. B., Marder, W., Neogi, T., et al. (2021) · Rheumatology · doi:10.1093/rheumatology/keab583 · Cited by 18
Rheumatoid Arthritis Disease Activity and Hospitalized Infection in a Large US Registry
Yun, H., Chen, L., Roy, J., Greenberg, J. D., Harrold, L. R., George, M., & Curtis, J. R. (2022) · Arthritis Care & Research · doi:10.1002/acr.24984 · Cited by 18
Self-citationLee, J., Singh, N., Gray, S. L., & Makris, U. E. (2022) · ACR Open Rheumatology · doi:10.1002/acr2.11503 · Cited by 20
“In a large observational study, GC use was associated with a dose-dependent increase in the risk of serious infection, even at doses of 5 mg or less per day (79).”
BackgroundLiu, Y., Yang, Y. P., Wang, M., Zhang, C., & Li, C. (2023) · Nanomedicine · doi:10.2217/nnm-2022-0211 · Cited by 18
Ruiz, J. I., Lei, X. J., Giordano, S. H., Zhao, H., Rajan, S. S., Lin, H. K., & Suarez-Almazor, M. E. (2025) · The Lancet Rheumatology · doi:10.1016/s2665-9913(24)00379-5 · Cited by 17
Palmowski, A., Nielsen, S. M., Boyadzhieva, Z., Hartman, L. M., Oldenkott, J., Svensson, B., Hafström, I., Wassenberg, S., Choy, E., Kirwan, J., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m23-0192 · Cited by 18
Understanding the multiple dimensions of ageing: 5Ms for the rheumatologist
Buehring, B., van Onna, M., Myasoedova, E., Lee, J., & Makris, U. E. (2024) · The Lancet Rheumatology · doi:10.1016/s2665-9913(24)00230-3 · Cited by 18
Gérard, A. O., Barbosa, S., Anglicheau, D., Couzi, L., Hazzan, M., Thaunat, O., Blancho, G., Caillard, S., Sicard, A., & French SOT COVID Registry (2022) · Transplantation · doi:10.1097/tp.0000000000004254 · Cited by 16
“Most of these effects are known to be dependent on the cumulative dose of corticosteroids, especially regarding the infectious risk.(16) Long-term preexisting corticosteroid exposure may, therefore, impair the establishment of an efficient immune response at the initial stages of the infection.”
BackgroundGeorge, M., Hsu, J. Y., Hennessy, S., Chen, L., Xie, F., Curtis, J. R., & Baker, J. F. (2021) · Epidemiology · doi:10.1097/ede.0000000000001422 · Cited by 19
“Herpes zoster vaccine (ever), N (%) 7,456 (7) 3,956 (6) −0.”
Self-citationHu, Y., Liu, J., Xin, L., Wan, L., Qi, Y., Li, Y., & Chen, Y. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s431124 · Cited by 15
“48,49 Therefore, we focused on designing alternative or auxiliary drug therapies that are robust and can effectively alleviate the toxicity and side effects associated with RA drugs used in Western medicine.”
BackgroundDelteil, A., Lambert, C., Pereira, B., Couderc, M., Malochet‐Guinamand, S., Pickering, M. E., de Naide, M. V., Mathieu, S., Soubrier, M., & Tournadre, A. (2023) · RMD Open · doi:10.1136/rmdopen-2023-003366 · Cited by 15
Tan, A. J., Streicher, J. L., Merola, J. F., & Noe, M. H. (2021) · Dermatology Online Journal · doi:10.5070/d327955114 · Cited by 14
“Even low-dose glucocorticoids, starting at 5mg or less per day, may confer an increased risk of serious infection in patients with rheumatoid arthritis (RA), [14].”
BackgroundXia, B., Song, B., Zhang, J., Zhu, T., & Hu, H. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.02.015 · Cited by 13
Bellan, M., Scotti, L., Ferrante, D., Calzaducca, E., Manfredi, G. F., Sainaghi, P. P., & Barone‐Adesi, F. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11112955 · Cited by 13
“In fact, the chronic use of corticosteroids is responsible for an increase in infection risk, even when used at lower than 5 mg/day [35].”
BackgroundWang, Q., Gao, Q.-C., Wang, Q.-C., Wu, L., Yu, Q., & He, P. F. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04426-7 · Cited by 12
“Currently, Nonsteroidal anti-inflammatory drugs [3], Glucocorticoids [4, 5], and Disease-Modifying Anti-Rheumatic Drugs (methotrexate, sulfasalazine, minocycline, hydroxychloroquine, and azathioprine) are commonly utilized as the primary pharmacological interventions for managing patients with RA These drugs exert the…”
BackgroundAdami, G., Bixio, R., Virelli, G., Galvagni, I., Mastropaolo, F., Morciano, A., Ruzzon, F., Messina, V., Fracassi, E., Gatti, D., et al. (2024) · Rheumatology · doi:10.1093/rheumatology/keae455 · Cited by 12
Salehi, T., Chapman, G. B., Farrah, T. E., Chapman, F. A., Pugh, D., Hunter, R. W., & Dhaun, N. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.04.030 · Cited by 13
“13,14 Combination cyclophosphamide-rituximab induction, with i.v. methylprednisolone followed by a rapid oral glucocorticoid taper, was shown to be effective and safe in an observational study of patients with AAV causing glomerulonephritis.”
The safety of antirheumatic drugs
Mücke, J., Simon, H., & Burmester, G. R. (2022) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2022.0064 · Cited by 12
Microbiota-assisted therapy for systemic inflammatory arthritis: advances and mechanistic insights
Li, B., Yang, B. K., Liu, X., Zhao, J., Ross, R. P., Stanton, C., Zhang, H., & Chen, W. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04498-6 · Cited by 12
“Glucocorticoids are a double-edged sword that can easily reduce joint swelling and stiffness while also causing notable side effects [28, 29].”
BackgroundImmunodeficiencies in Adults: Key Considerations for Diagnosis and Management
Regina, J., Doms, J., Kampouri, E., Gerber, C., Manuel, O., Bart, P., Candotti, F., & Comte, D. (2025) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-025-09103-9 · Cited by 15
“Glucocorticoids exert anti-inflammatory and immunosuppressive effects in a dose and duration-dependent manner [31], and may lead to hypogammaglobulinemia and CD4 lymphopenia [22, 32].”
Bridgewater, S., Shepherd, M. A., Dawson, J., Richards, P., Silverthorne, C. A., Ndosi, M. E., Almeida, C., Black, R. J., Cheah, J. T. L., Dures, E. K., et al. (2023) · Rheumatology · doi:10.1093/rheumatology/kead081 · Cited by 11
“Patients taking GC therapy can have concerns about the increased risk of infection [30], particularly during the COVID-19 pandemic [31], and concerns about secondary conditions, e.g. osteoporosis.”
BackgroundTong, Z., Zeng, X., Huang, F., Wu, Z., Chen, H., Zhang, Y., Chen, J., Luo, R., Chen, F., Zou, Y., et al. (2025) · American Journal of Clinical Dermatology · doi:10.1007/s40257-025-00923-1 · Cited by 11
“Regarding the long-term safety of a longer dosing interval of JAK inhibitors in elderly patients, the current lack of broad post-marketing safety data poses challenges for clinicians in assessing the risk–benefit ratio, especially in the treatment of AD [18].”
Management of Late-Onset Rheumatoid Arthritis with Treat-to-Target Strategy
Harigai, M., & Sugihara, T. (2025) · Drugs & Aging · doi:10.1007/s40266-025-01195-4 · Cited by 11
“Insurance database studies in the USA [109] and Canada [110] found a significant dose-dependent increased risk of serious infections in older patients with RA, and even prednisolone at 5 mg daily or less was a risk for serious infections [109].”
Li, D., Ding, L., Luo, J., & Li, Q.-G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1192369 · Cited by 10
Common Instances of Low-value Care in Inflammatory Bowel Diseases
Singh, S., Velayos, F. S., & Rubin, D. T. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.09.043 · Cited by 11
Tapering of disease-modifying antirheumatic drugs: an overview for daily practice
Maassen, J. M., van Ouwerkerk, L., & Allaart, C. F. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00224-1 · Cited by 10
Frede, N., Rieger, E., Lorenzetti, R., Nieters, A., Venhoff, A. C., Hentze, C., von Deimling, M., Bartholomä, N. M., Thiel, J., Voll, R. E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1040725 · Cited by 10
The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence
Luís, M., Boers, M., Saag, K., Buttgereit, F., & da Silva, J. A. P. (2022) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000870 · Cited by 11
“Park et al. [41] looked into the incidence and risk factors of PCP in patients with rheumatic diseases exposed to PDN-eq less than 15mg/day or 15– 30mg/day, over a 14-year period.”
BackgroundInfluentialLeding, C., Meddis, A., Holler, J. G., Burisch, J. M., Kragstrup, T. W., Skov, L., & Benfield, T. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.02.005 · Cited by 9
Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database
Iudici, M., Mongin, D., Siegert, E., Carreira, P. E., Distler, J. H. W., Henes, J. C., Zanatta, E., HACHULLA, E., Luca, G. D. D., Müller, C. D. S., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac533 · Cited by 9
Zacay, G., & Heymann, A. D. (2023) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5602 · Cited by 9
“46, respectively).(19) Another study of patients with rheumatoid arthritis found higher rates of infections among patients who were treated with corticosteroids, when the most common infections were urinary infection, pneumonia, bacteremia or septicemia, and skin or soft tissue infections.”
BackgroundSugihara, T., Kawahito, Y., Kaneko, Y., Tanaka, E., Yanai, R., Yajima, N., Kojima, M., & Harigai, M. (2024) · Modern Rheumatology · doi:10.1093/mr/roae026 · Cited by 9
Lee, J., Martindale, J., Wallace, B. I., Singh, N., Makris, U. E., & Bynum, J. (2025) · ACR Open Rheumatology · doi:10.1002/acr2.70013 · Cited by 8
“6,19 To assess changes in long-term GC use, we divided the follow-up period into four three-month quarters (Q1, Q2, Q3, and Q4), beginning with the index date.”
Lovegrove, F. E., Sauder, M. B., Mufti, A., Beecker, J. R., Dutz, J. P., Kirchhof, M. G., Mydlarski, P. R., Purdy, K. S., & Lansang, P. (2025) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/12034754251351854 · Cited by 8
“46,47 Patients beginning long-term corticosteroids should consider vitamin D supplements, adequate calcium (ideally from dietary sources), and bisphosphonate therapy, and undergo usual monitoring including blood pressure, blood sugar, and bone density.”
Multiple morbidities are associated with serious infections in patients with rheumatoid arthritis
Kimbrough, B. A., Crowson, C. S., Lennon, R. J., Davis, J. M., Strangfeld, A., & Myasoedova, E. (2024) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2024.152386 · Cited by 8
Matsumoto, T., Sugihara, T., Hosoya, T., Ishizaki, T., Kubo, K., Kamiya, M., Baba, H., Tsuchida, M., Hirano, F., Kojima, M., et al. (2023) · Rheumatology Advances in Practice · doi:10.1093/rap/rkae019 · Cited by 8
“75 and LORA 75 groups has also been reported in other studies [44 – 46].”
ResultOhmura, S., Matsui, H., Miyamoto, T., Shichi, D., Masui, T., Ichijo, K., Homma, Y., Fujioka, H., Nagai, T., & Nakashima, K. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.02.015 · Cited by 8
Predictors of serious infections in rheumatoid arthritis—a prospective Brazilian cohort
de Almeida, A. L. B., Guimarães, M. F. B. D. R., Pinto, M. R. D. C., Pereira, L. R., Gomides, A. P. M., Bonfiglioli, K. R., Louzada‐Júnior, P., Giorgi, R. D. N., de Castro, G. R. W., Radominski, S., et al. (2024) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-024-00363-1 · Cited by 8
“This risk increases with the dose escalation of the medication [8, 11].”
BackgroundResultRisk factors associated with development of coinfection in critically Ill patients with COVID-19
Orsini, E. M., Sacha, G. L., Han, X., Wang, X., Duggal, A., & Rajendram, P. (2022) · Acute and Critical Care · doi:10.4266/acc.2022.00136 · Cited by 8
“Corticosteroids are known to be associated with an increased risk of infection, but their use has increased in patients with COVID-19 since benefit was shown in the RECOVERY trial (dexamethasone in hospitalized patients with Covid-19 by the RECOVERY Collaborative Group) [27,28].”
BackgroundXie, W., Huang, H., & Zhang, Z. (2023) · Rheumatology and Therapy · doi:10.1007/s40744-022-00527-9 · Cited by 8
Jacquot, R., Sève, P., Mulier, G., Hankard, A., Maalouf, G., Kodjikian, L., Jammal, T. E., Jamilloux, Y., Toutée, A., de Gauzy, T. S., et al. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2025.05.026 · Cited by 7
Huang, W., Chuo, C., Lin, C., Chen, Y., Lin, W., Tuckwell, K., Jones, N. S., Galanter, J., & Lindsay, L. (2022) · Rheumatology and Therapy · doi:10.1007/s40744-022-00525-x · Cited by 7
Zou, J., Zhang, Y., Niu, J., Song, D., Huang, Z., Li, Z., Liu, T., Meng, B., Shi, Q., Zhu, X., et al. (2024) · Orthopaedic Surgery · doi:10.1111/os.14087 · Cited by 7
Galvao, R. W., Curtis, J. R., Harrold, L. R., Wu, Q., Xie, F., & George, M. (2023) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5660 · Cited by 7
Self-citationJo, H.-G., Seo, J., Baek, E., & Lee, D. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107616 · Cited by 7
Kaneko, Y., Kameda, H., Ikeda, K., Yamashita, K., Ozaki, R., & Tanaka, Y. (2023) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14848 · Cited by 6
Vasavada, K. D., Jazrawi, L. M., & Samuels, J. (2021) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-021-09720-9 · Cited by 6
Sakellariou, G., Scirè, C. A., Rumi, F., Carrara, G., Zanetti, A., Cerra, C., Migliazza, S., Bugatti, S., & Montecucco, C. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02824-8 · Cited by 7
“Very recently, the 23-year follow-up of the COBRA study has shown no increased risk compared to the general population, suggesting an overall beneficial role of the initial intensive treatment with GC, although the effect of these drugs was not specifically addressed [14].”
BackgroundResultThe evolving comorbidity landscape of rheumatoid arthritis
Brooks, R. T., England, B. R., Kronzer, V. L., & Crowson, C. S. (2026) · Nature Reviews Rheumatology · doi:10.1038/s41584-026-01386-2 · Cited by 5
“…even low doses (≤7.5 mg prednisolone daily equivalent) substantially increase the risk of Staphylococcus aureus bacteraemia, and higher doses are associated with a nine-fold increase in infection risk, with a clear dose-dependent association with hospitalization-requiring infections 99,100 .”
InfluentialLow-Dose Glucocorticoids in Older Patients with Rheumatoid Arthritis: What Does the Evidence Say?
Sugihara, T., Tanaka, E., & Matsui, T. (2024) · Drugs & Aging · doi:10.1007/s40266-024-01133-w · Cited by 6
“Similar results were obtained in patients ≥ 75 years of age [55].”
Aronova, E. S., Belov, B. S., & Гриднева, Г. И. (2023) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2023-3-89-95 · Cited by 5
Egalini, F., Caprino, M. P., Gaggero, G., Cappiello, V., Giannelli, J., Giaccherino, R. R., Pagano, L., & Giordano, R. (2021) · Endocrines · doi:10.3390/endocrines2030018 · Cited by 5
“also found that infection risk in patients treated with daily doses of prednisone 5 mg or less per day was significantly higher [138].”
BackgroundVasavada, K. D., Shankar, D. S., Avila, A., Lin, C. C., Marulanda, D., Jazrawi, L. M., & Samuels, J. (2023) · The Knee · doi:10.1016/j.knee.2022.12.017 · Cited by 5
Shao, X., Zhang, M., Hu, S., & Yang, Z. (2025) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70042 · Cited by 5
“39 Therefore, we propose that preconditioning SMSCs with GCs may potentiate the antiarthritic benefits of their derived EVs (GCs-EVs) while mitigating the negative consequences typically associated with GC therapy.”
Metadata
- Authors
- George, M. D., Baker, J. F., Winthrop, K., Hsu, J. Y., Wu, Q., Chen, L., Xie, F., Yun, H., & Curtis, J. R.
- Affiliations
- University of Pennsylvania (US)
- Philadelphia VA Medical Center (US)
- Oregon Health & Science University (US)
- University of Alabama at Birmingham (US)
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2020-12-01
- Volume
- 173
- Issue
- 11
- Pages
- 870-878
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- PMC
- PMC8073808
- OpenAlex
- W3087498606
- Cited by
- 198
- References
- 30
- Citations by year
- 2026: 35 · 2025: 33 · 2024: 32 · 2023: 38 · 2022: 38 · 2021: 19 · 2020: 3
- FWCI
- 18.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (1K23AR073931-01)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- rheumatoid arthritis, low-dose glucocorticoids, hospitalized infection, infection risk, disease-modifying antirheumatic drugs, glucocorticoid dose, long-term glucocorticoid use, adverse drug reactions, Medicare beneficiaries, cumulative incidence, inverse probability weighting, propensity score matching, immunosuppression
- MeSH terms
- Aged, Arthritis, Rheumatoid, Female, Glucocorticoids, Hospitalization, Humans, Infections, Male, Retrospective Studies, Risk Factors, Antirheumatic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.